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Abstract
Background: There are a wide variety of medications available for the treatment of hyperglycemia
in diabetes, including some categories developed in recent years. The goals of this study were to
describe the glycemic medication profiles in a cohort of adult patients enrolled in primary care, to
compare the regimens with measures of glycemic control, and to describe potential
contraindicated regimens.
Methods: One thousand and six subjects with diabetes cared for in community practices in the
Northeast were interviewed at home at the time of enrollment in a trial of a diabetes decision
support system. Laboratory data were obtained directly from the clinical laboratory. Current
medications were obtained by direct observation of medication containers by a research assistant.
Results: The median age of subjects was 63 years; 54% were female. The mean A1C was 7.1%,
with 60% of subjects in excellent glycemic control (A1C < 7%). Ninety percent of patients were
taking 2 or fewer medications for glycemic control, with a range of 0 to 4 medications. Insulin was
used by 18%. As the number of diabetes medications increased from 0 to 4, the A1C increased
from 6.5% to 9.2% (p < 0.001). The association between glycemic control and number of glycemic
medications was confirmed using logistic regression, controlling for potential confounders. Almost
20% of subjects on metformin or thiazolidenediones had potential contraindications to these
medications.
Conclusion: Patients with diabetes cared for in primary care are on a wide variety of medication
combinations for glycemic control, though most are on two or fewer medications. A greater
number of diabetes medications is associated with poorer glycemic control, reflecting the
limitations of current pharmacotherapy. One quarter of patients are on glycemic medications with
potential contraindications.
Background
Despite evidence that optimal diabetes care can result in
reduced complications and improved economic out-
comes, such care is often not achieved [1-4]. Through the
1990s, the number of primary care visits among patients
with diabetes listing at least 5 prescription medications
increased from 18% to 30%, and the proportion of visits
in which more that one medication for glycemic control
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cemic agent use increased from 45% to 53%, and combi-
nation therapy with insulin and an oral agent increased
from 3% to 11% [6].
While there are a wide variety of options for pharmaco-
therapy of diabetes, there is no one recommended regi-
men [7]. New classes of medications have been
introduced since 1999, including the thiazolidenediones
(TZDs), acarbose, and both ultra-short acting and 24-hour
insulin analogues. It is not clear how the addition of these
new medication classes has changed the landscape of
pharmacotherapy of diabetes.
Our goals in this study were: 1) to describe the glycemic
medication profiles and the associated level of glycemic
control in a cohort of adult patients in primary care set-
tings, and 2) to analyze the medication profiles for poten-
tial medication contraindications.
Methods
This study was part of a larger project, the Vermont Diabe-
tes Information System (VDIS), a cluster-randomized trial
of a laboratory-based diabetes decision support system in
a sample of 7338 adults with diabetes in northern New
England [8]. A detailed description of the recruitment
strategy has been reported [8]. In brief, the patient sub-
jects comprised the entire roster of patients with a diagno-
sis of diabetes (confirmed by the primary care provider)
cared for in 64 Primary Care practices in Vermont and
adjacent New Hampshire and northern New York.
Patients receiving most of their diabetes care from an
endocrinologist, or those with significant cognitive
impairment were excluded. A field survey was completed
at study baseline in a sub-sample of subjects in order to
provide a better understanding of the non-laboratory fea-
tures of diabetes. Patient names were randomly sorted
and patients contacted by telephone until a sample of
approximately 15% of patients from each practice agreed
to an interview. We attempted to contact 4209 patients
and reached 1576. Of these, 1006 agreed to be inter-
viewed; they comprise the dataset for our analyses. We
have limited data on the non-interviewed patients (N =
6331). They were younger (63 vs. 65 years, p < 0.001 by
ttest), slightly less likely to be women (50 vs. 54%, p =
0.01 by chi square analysis), but similar in mean A1C (7.1
vs. 7.1, p = 0.14, ttest).
Demographic information including age, sex, race, ethnic-
ity, education, income, marital status, functional status,
and history of comorbid conditions were obtained by
questionnaire. Prior to the interview, patients were
instructed to gather all current medications, including
over the counter preparations, for review by the research
assistant. The medication list was ascertained by direct
observation of the pill containers with recording of medi-
cation name, dose, frequency and route of administration.
Adherence was measured by the difference between the
number of expected doses of medication per week and the
number reported in the past week. Medications taken "as
needed" were not included in the adherence measure.
The interviews occurred between July 2003 and March
2005. Most laboratory data were obtained from the
patients' local clinical laboratories, which all use the same
Diabetes Control and Complications Trial/Epidemiology
of Diabetes Interventions and Complications high per-
formance liquid chromatography (HPLC) method for the
determination of glycosolated hemoglobin A1C (A1C).
Less than 1% of A1C tests were done using the Bayer DCA
2000 immunoassay point of care instrument, which has
been shown to compare favorably with the HPLC method
[9]. We have not determined the analytic variation in the
measurement of A1C between the eleven participating
laboratories, but they are all hospital-based, accredited
laboratories. The research protocol was carried out in
compliance with the Helsinki Declaration and was
approved by the Human Subjects Committee of the Uni-
versity of Vermont. The interview subjects provided writ-
ten informed consent and were reimbursed $20 for their
time.
Statistical approach
We performed a cross sectional analysis of the interviewed
subjects at the time of enrollment in the VDIS trial. We
used descriptive statistics to describe the proportion of
subjects using the various medication regimens, and the
subjects with potential contraindications. We used Spear-
man rank-order correlation [10] and a non-parametric
test [11] to assess statistical significance of associations.
To further explore the relationship between glycemic con-
trol and the number of medications, we performed logis-
tic regression using A1C < 7% as the outcome variable and
the number of glycemic medications as the primary pre-
dictor variable [12]. We then adjusted for possible con-
founding variables that represent social and clinical
factors that, if distributed differently among patients on
differing numbers of glycemic medications, could con-
found the relationship between medication count and
glycemic control. The potential confounders tested were
age, sex, race (white vs. other), marital status (married or
living as married vs. other), high school education (yes/
no), income (in seven ordered categories), five insurance
types (private, Medicare, Medicaid, Military or Veterans
Affairs, none), duration of diabetes, use of insulin, comor-
bidity (Self-Administered Comorbidity Questionnaire)
[13], driving distance to the primary care physician's
office [14], functional status (SF-12 Mental and Physical
Component Scores) [15], insurance coverage for medica-Page 2 of 6
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endocrinologist (yes/no), and visit frequency (number of
visits with primary provider in the past month). Further
description of the study protocol and variables has been
previously reported [8].
All analyses were carried out using Stata version 8.2 (Stata
Corporation, College Station, TX).
Results
The demographic characteristics and level of physiologic
control are noted in Table 1. The mean A1C was 7.1% and
the proportion of subjects with excellent glycemic control
(A1C below 7%) was 60%. Over 95% of the patients were
white, with three fourths high school graduates, and 57%
earning < $30,000 per year. Mental and physical function-
ing as measured by the SF-12 Mental Component Sum-
mary and Physical Component Summary scales were
similar to national norms for patients with diabetes [15].
Only 2.1% of the subjects were without health insurance.
This reflects the recruitment strategy in which patients
under the care of a primary care physician were eligible for
participation. Furthermore, Vermont has a relatively low
proportion of uninsured persons at 9.9% [16] and a rela-
tively high proportion with Medicaid coverage (17.8%)
[17]. The majority of subjects had partial coverage of their
medications by insurance, and 14% had full coverage.
The median number of daily prescription medications for
all conditions was 6 (range 0–24). Patients reported 90%
adherence with the expected number of doses in the week
prior to the interview. The diabetes medication profiles of
the subjects are shown in Table 2; one quarter were taking
no medications, 65% were on one or two diabetes medi-
cations, and about 10% were on three or four medications
for diabetes. As the number of diabetes medications
increases, the proportion of patients with excellent glyc-
emic control (A1C < 7%) decreases steeply and signifi-
cantly (p < 0.001). The mean A1C increased from 6.5%
for patients on no medications to 9.2% for subjects on 4
medications (Spearman rho = 0.35, p < 0.001).
In the unadjusted logistic regression model, the likeli-
hood of a subject having excellent glycemic control (A1C
< 7%) was significantly related to the number of glycemic
medications (OR = 0.48/additional medication, P <
0.001, 95% CI = 0.42, 0.56). After adjustment for poten-
tial confounders (see methods) this relationship did not
change appreciably (OR = 0.49/additional medication, P
< 0.001, 95% CI = 0.41, 0.59).
In an effort to evaluate potentially harmful medication
regimens, we looked at the proportion of subjects receiv-
ing therapy that may be contraindicated according to the
manufacturer's recommendation. These results are shown
in Table 3. Metformin is relatively contraindicated in
patients with renal dysfunction; we found 10 of 288 sub-
jects on metformin with an abnormal creatinine level (all
abnormal values were between 1.5 and 2.0 mg/dl). Con-
gestive heart failure is a relative contraindication to both
metformin and thiazolidenediones (TZDs). We found
that 14% of subjects on metformin and 18% of subjects
on TZD therapy reported a history of heart failure. If all
potential contraindications to metformin are combined,
19% of subjects had a potential contraindication. A total
of 25% of subjects had a potential contraindication to one
of these two medications.
Discussion
We have described the medication regimens in a cohort of
patients with diabetes receiving care in primary care prac-
tices in the Northeast. For glycemic control most of these
patients (90%) were treated with either no medications,
single drug, or two drug combinations. While these
patients were treated with what appear to be relatively
simple regimens, 40% were not at the American Diabetes
Association target for glycemic control of <7%.
Table 1: Baseline characteristics of the VDIS interview 
population
Characteristic N = 1006
Age in years, median (range) 65 (22–93)
Sex, % female 54%
Race (% White) 97%
Education (high school graduate), % 75%
Smoking, % 17%
Income (< $30,000/y), % 59%










Duration of DM, years, median (range) 6.7 (0.2–62)
BMI
Normal (BMI < 25) 10%
Overweight (BMI 25–29.9) 23%
Obese (BMI >= 30) 67%
A1C %, mean (SD) 7.1 (1.3)
A1C in excellent control [<7%], % 57%
Excellent BP control (<= 130/80), % 25%
Poor BP control (>140/90), % 51%
SF-12 PCS, mean (SD) 41 (12)
SF-12 MCS, mean (SD) 50 (11)
Total prescription medications, median(range) 6 (0–24)Page 3 of 6
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lowering comparing sulfonylureas, metformin and TZDs.
Initial therapy with an oral agent in Type 2 diabetes will
decrease the A1C by about 1–2 percentage points [6].
Over time, most patients do not maintain glycemic con-
trol on a single agent [5], and combining a second or third
oral agent typically produces additive, not synergistic
effects. We have demonstrated that as the number of glyc-
emic medications increases, the level of glycemic control
worsens. This association persists after controlling for
demographic and treatment variables. It most likely
reflects confounding by intention: subjects with the high-
est blood sugar or A1C levels are preferentially put on
more aggressive regimens, but these regimens are only
partially effective in controlling hyperglycemia.
Two recent studies have addressed the complexity of DM
regimens using data from large national datasets. Koro
Table 2: Medication profiles of the VDIS subjects (N = 1006)
Medication Regimen N Proportion of population, % Excellent control (A1C < 7%), % Mean A1C, %
Categorized by number of medications
No diabetes medications 242 25 80 6.5
Monotherapy 402 40 58 7.2
2 Drugs 254 25 46 7.4
3 Drugs 103 10 29 7.6
4 Drugs 5 < 1 0 9.2
Categorized by type of medication
Any oral medication 670 67 51 7.3
Oral medication(s) alone 578 58 54 7.2
Any insulin therapy 186 19 35 7.8
Insulin alone 94 9 41 7.6
Both oral medication and insulin 92 9 29 7.9
Monotherapy regimen detail
Sulfonylurea 123 12 58 7.1
Metformin 126 13 66 7.1
TZD 55 5 67 6.8
Insulin 94 9 41 7.6
2-Drug Oral Combination detail
Sulfonylurea + Metformin 103 10 41 7.5
Sulfonylurea + TZD 49 5 49 7.2
Metformin + TZD 50 5 60 7.1
3 Drug Oral Combination detail
Sulfonylurea + Metformin + TZD 67 7 35 7.4
Insulin therapy detail
Insulin glargine 90 9 30 8.0
Any insulin + 1 oral agents 54 5 38 7.8
Any insulin + 2 oral agents 23 2 20 7.9
Table 3: Potential medication contraindications in VDIS subjects
Potential Contraindication* Number % of eligible subjects §
Metformin and Creatinine >= 1.5 mg/dl 15 4%
Metformin and "kidney problems" 15 4%
Metformin and "CHF" 56 14%
Metformin and any of the above 75 19%
TZD and "CHF" 49 19%
Any potential contraindication 252 25%
* Subjects may be in more than one category
§403 subjects on metformin; 264 subjects on TZDPage 4 of 6
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Examination Survey data from 1988 to 2000, showed oral
hypoglycemic agent use increased from 45% to 53%,
insulin use decreased from 24% to 16% and combination
therapy with insulin and an oral agent increased from 3%
to 11% [6]. Grant et al. using data from the Ambulatory
Medical Care Survey from 1991–2000 found that oral
hypoglycemic agent use increased from 37% to 51% of
visits and insulin use decreased from 25% to 15%[5]. We
found an even higher proportion of subjects on oral
hypoglycemic agents (67%), and a similar proportion on
insulin (18%). The important distinctions between our
study and previous reports are: 1) our data collection
reflects care in 2003–2005 including therapies introduced
since 2000, and 2) our subjects are representative of
patients who are receiving care from a primary care pro-
vider. With the addition of the TZDs and 24-hour insulin
analogues, it would appear that the use of oral medica-
tions has been continuing to increase, while insulin use is
stable.
In Type 2 DM, insulin is often used after other treatments
have failed. Some authors, recognizing that multi-drug
oral combinations are not particularly effective, have sug-
gested that insulin is underused [18-20]. While there are
barriers to starting insulin in Type 2 DM [21], there is
increasing recognition of ways to address those barriers
[22]. Because of the complexity of medication options in
Type 2 DM and the heterogeneity of the disease process,
treatment options should be individualized based on the
needs and preferences of the prescriber and the patient.
We identified potential medication contraindications by
comparing the medication profiles with self-reported
comorbid conditions and with abnormal lab values. Both
metformin and the TZDs have CHF as a relative contrain-
dication [23-25]. We found that about 15% of subjects
with self-reported CHF were on one or the other of these
medications. This finding may indicate a prescribing
problem, but is limited by the lack of data regarding the
intentions of the prescriber and the inherent inaccuracies
of self-report of comorbid conditions. Furthermore, new
uncertainty regarding the contraindication to metformin
use in CHF was recently introduced by findings that mor-
tality and hospitalization were actually lower among CHF
patients in Saskatchewan prescribed metformin versus
sulfonylureas [26].
We looked at potential renal contraindications in subjects
on metformin therapy and found that fewer that 5% of
subjects had either mildly elevated creatinine values (all <
2.0 mg/dl) or self-reported kidney problems. The larger
decision support system study in which these subjects are
enrolled automatically sends alerts to the physician warn-
ing against the use of metformin whenever an abnormal
creatinine value is reported, providing a safeguard against
continued use. This safeguard was not yet in place when
the data were collected.
This study has several strengths. The VDIS study popula-
tion (n = 7338) comprises the entire roster of patients
with diabetes receiving care in the practices enrolled in the
larger controlled trial. The interviewed subjects are a ran-
domly selected subset of this population, and are there-
fore likely to be representative of patients cared for in
community primary care settings in the Northeast. Ascer-
tainment of the medication profiles was by direct observa-
tion by a research assistant in the patient's home and not
subject to the biases inherent in administrative pharmacy
databases.
This study also has several limitations. We do not have
data on the prescribing intent of the PCPs or side effects
experienced by the patients, so we cannot know what bar-
riers may exist to the advancement of pharmacotherapy in
an individual patient. We did not include patients whose
primary diabetes care is by an endocrinologist, so our
results may not generalize to patients cared for in a spe-
cialty setting. This may especially exclude patients with
highly refractory DM or those using insulin pump ther-
apy. We do not distinguish between patients with Type 1
and Type 2 DM, though from a clinician's point of view,
this distinction may be less important than understanding
the pathophysiology and response to treatment in an
individual patient in order to direct therapy [27,28].
Conclusion
Patients with diabetes cared for in primary care are on a
wide variety of medication combinations for glycemic
control, though most are on two or fewer medications. A
greater number of diabetes medications is associated with
poorer glycemic control, reflecting the limitations of cur-
rent pharmacotherapy. One quarter of patients are on gly-
cemic medications with potential contraindications.
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